Aman Pande, MD
Pulmonary Disease · Westlake, OHNPI 1275797656
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,810 of the $43,314 with a category attached, or 80.4%. Boehringer Ingelheim accounts for 99.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $11,880 and has fallen 58.4% since, to $4,943 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $984.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$43K
- Insmed, Inc.$166
- GSK$36
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9
Across 6 payments — averaging $7492.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$26K
- Boehringer Ingelheim$19K
What the payments were for
- Consulting fees$4,0089%
- Speaking & faculty fees$34,81080%
- Travel & lodging$2,9667%
- Food & beverage$1,5294%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 40 | $43,102 |
| Insmed, Inc. | 2 | $166 |
| GSK | 1 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
How this compares
$43,314 in reported general payments places this provider in the 90th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 111 | $1,420,128 |
| Pirfenidone | 124 | $448,490 |
| Humira PenAdalimumab | 12 | $163,483 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $86,218 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $24,661 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,628 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $20,514 |
| Mycophenolate Mofetil | 72 | $9,470 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,353 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,095 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,312 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $5,269 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,017 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,506 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $43,102 | $1,447,851147 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $36 | $141,210185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Westlake
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
- Jean ElwingCincinnati$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.